Skip to main content
Industry

Spinout Spotlight: Lieping Chen, M.D., Ph.D.

Lieping Cheng headshot
United Technologies Corporation Professor in Cancer Research and Professor of Immunobiology, of Dermatology and of Medicine (Medical Oncology); Co-Leader, Cancer Immunology, Yale Cancer Center

Yale Spinout Success Snapshot - NextCure

  • Lieping Chen is the United Technologies Corporation Professor in Cancer Research and the pioneer of Immuno-checkpoint modulators (Opdivo of BMS and Keytruda of Merck).
  • He founded NextCure to develop new cancer drugs.
  • Raised a record $67M Series A funding
  • In Nov. 2018, announced the completion of a $93million series B equity financing.
  • NextCure is now a publicly traded company since its IPO in May of 2019